Scientists think ketamine relieves depression and anxiety by altering GluN1-2B-2D’s movements, but the effects can vary ...
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
A recent case report published in the Journal of Psychoactive Drugs tells the story of a middle-aged man who underwent an ...
A Calgary clinic has received provisional accreditation to provide a novel way of administering the psychedelic drug ketamine ...
New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.
The drug is approved for use by doctors and veterinarians as an anesthetic—but is also capable of producing hallucinogenic ...
Every generation seems to have an association with an illegal drug. Baby boomers had LSD, Gen X had pills and millennials had ...
The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders.
Ketamine also has come under increasing scrutiny as a treatment recently, with studies suggesting that for some patients it ...
Depression hits the whole body, speeding the onset of long-term physical ills as people age, new research contends.
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...